In a phase I/II clinical trial, derazantinib exhibited encouraging anti-tumor efficacy and tolerable safety profiles among patients diagnosed with advanced, unresectable ICC harboring FGFR2 fusion, resulting in a notable response rate of 20.7% and a disease control rate of 82.8% [186]. The gene discussed is FGFR2; the disease is neoplasm.